Payment overview · 2025
General Payments
$1,171.34
55 reported records · 22 companies
Healthcare provider profile · identity verified
David Mark Zelechoski, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LEWISBURG, PA · NPI 1356360085
Verified facts
What the public records show
CMS Open Payments records show David Mark Zelechoski, M.D. received $1,171.34 in general payments during 2025 across 55 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Paxlovid, Prolia, Rybelsus, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 417 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $239.59 | 20.4% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $110.33 | 9.4% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $94.47 | 8.1% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $91.67 | 7.8% | 5 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $69.01 | 5.9% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $60.67 | 5.2% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $59.48 | 5.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.27 | 4.4% | 3 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $48.93 | 4.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.81 | 4.0% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $42.47 | 3.6% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $38.57 | 3.3% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $34.75 | 3.0% | 2 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $32.02 | 2.7% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $24.42 | 2.1% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $23.46 | 2.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.53 | 1.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.45 | 1.5% | 1 | 2025 |
| AppliedVR Inc | Unresolved — no canonical attribution shown | $17.40 | 1.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.34 | 1.5% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $17.10 | 1.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.60 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,171.34 | 55 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $179.68 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $109.52 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $94.47 | 5 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $69.01 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $60.67 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $59.48 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $56.19 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.19 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $51.31 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $51.31 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $49.61 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $48.93 | 2 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $48.93 | 2 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $48.93 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $46.81 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $42.47 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $38.57 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $35.88 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.48 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.83 | 2 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $32.02 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $23.46 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| RelieVRx Normalized: relievrx |
Device | AppliedVR Inc | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.34 | 2 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 417 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 125 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 122 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 108 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 22 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 106 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
106 | 28 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
90 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
125 | 27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
108 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
417 | 81 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 918 | 187 |
| Atorvastatin Calcium | Atorvastatin Calcium | 844 | 220 |
| Metoprolol Succinate | Metoprolol Succinate | 688 | 165 |
| Pantoprazole Sodium | Pantoprazole Sodium | 625 | 138 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 592 | 141 |
| Lisinopril | Lisinopril | 523 | 133 |
| Trazodone Hcl | Trazodone Hcl | 518 | 113 |
| Amlodipine Besylate | Amlodipine Besylate | 473 | 118 |
| Omeprazole | Omeprazole | 469 | 119 |
| Famotidine | Famotidine | 442 | 102 |
| Eliquis | Apixaban | 417 | 81 |
| Prednisone | Prednisone | 415 | 222 |
| Hydrochlorothiazide | Hydrochlorothiazide | 405 | 107 |
| Gabapentin | Gabapentin | 377 | 81 |
| Torsemide | Torsemide | 343 | 74 |
| Tramadol Hcl | Tramadol Hcl | 336 | 88 |
| Escitalopram Oxalate | Escitalopram Oxalate | 323 | 80 |
| Sertraline Hcl | Sertraline Hcl | 318 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 306 | 65 |
| Metformin Hcl Er | Metformin Hcl | 301 | 77 |
| Simvastatin | Simvastatin | 296 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 282 | 67 |
| Losartan Potassium | Losartan Potassium | 263 | 70 |
| Irbesartan | Irbesartan | 236 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 219 | 51 |
| Metformin Hcl | Metformin Hcl | 216 | 47 |
| Doxazosin Mesylate | Doxazosin Mesylate | 209 | 49 |
| Montelukast Sodium | Montelukast Sodium | 208 | 52 |
| Furosemide | Furosemide | 182 | 42 |
| Potassium Chloride | Potassium Chloride | 168 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 163 | 38 |
| Allopurinol | Allopurinol | 157 | 37 |
| Atenolol | Atenolol | 152 | 41 |
| Celecoxib | Celecoxib | 144 | 35 |
| Donepezil Hcl | Donepezil Hcl | 142 | 28 |
| Clonazepam | Clonazepam | 138 | 26 |
| Cefdinir | Cefdinir | 137 | 111 |
| Lorazepam | Lorazepam | 132 | 43 |
| Finasteride | Finasteride | 128 | 28 |
| Bupropion Xl | Bupropion Hcl | 126 | 28 |
| Farxiga | Dapagliflozin Propanediol | 125 | 27 |
| Jardiance | Empagliflozin | 122 | 19 |
| Meloxicam | Meloxicam | 122 | 31 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 120 | 22 |
| Ezetimibe | Ezetimibe | 119 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 117 | 20 |
| Carvedilol | Carvedilol | 115 | 23 |
| Ozempic | Semaglutide | 108 | 21 |
| Xarelto | Rivaroxaban | 107 | 25 |
| Synthroid | Levothyroxine Sodium | 106 | 28 |
| Warfarin Sodium | Warfarin Sodium | 103 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 102 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 100 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 25 |
| Spironolactone | Spironolactone | 94 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 25 |
| Azithromycin | Azithromycin | 91 | 60 |
| Myrbetriq | Mirabegron | 90 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 90 | 56 |
| Alprazolam | Alprazolam | 87 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 31 |
| Januvia | Sitagliptin Phosphate | 84 | 12 |
| Mirtazapine | Mirtazapine | 84 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 80 | 20 |
| Propranolol Hcl Er | Propranolol Hcl | 80 | 20 |
| Buspirone Hcl | Buspirone Hcl | 78 | 20 |
| Glimepiride | Glimepiride | 78 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 74 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 33 |
| Valsartan | Valsartan | 67 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 16 |
| Amoxicillin | Amoxicillin | 62 | 45 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 60 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 14 |
| Colestipol Hcl | Colestipol Hcl | 58 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 28 |
| Ipratropium Bromide | Ipratropium Bromide | 57 | 18 |
| Memantine Hcl | Memantine Hcl | 57 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 57 | 22 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 54 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 36 |
| Trulicity | Dulaglutide | 49 | 13 |
| Aripiprazole | Aripiprazole | 48 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 48 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | suppressed |
| Cephalexin | Cephalexin | 44 | 33 |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 43 | 11 |
| Pregabalin | Pregabalin | 43 | suppressed |
| Primidone | Primidone | 43 | suppressed |
| Lamotrigine | Lamotrigine | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 37 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 11 |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Premarin | Estrogens, Conjugated | 33 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 32 | suppressed |
| Clotrimazole | Clotrimazole | 32 | 21 |
| Diazepam | Diazepam | 32 | suppressed |
| Repatha Sureclick | Evolocumab | 32 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 31 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | suppressed |
| Invokana | Canagliflozin | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 28 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 21 |
| Telmisartan | Telmisartan | 26 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 26 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 13 |
| Fluconazole | Fluconazole | 24 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 16 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 23 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 23 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 21 |
| Risperidone | Risperidone | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Colchicine | Colchicine | 20 | 12 |
| Glipizide | Glipizide | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Febuxostat | Febuxostat | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Rufinamide | Rufinamide | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Invokamet Xr | Canagliflozin/Metformin Hcl | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Cimetidine | Cimetidine | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Travoprost | Travoprost | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,171.34 · 55 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Arikayce, BREZTRI, Brinsupri, COMIRNATY, CeQur Simplicity, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, Flector, GEMTESA, JARDIANCE, Licart, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PAXLOVID, PREVNAR 20, PROLIA, Prolastin-C Liquid, QUTENZA, REPATHA, RelieVRx, Rybelsus, SYNTHROID, Tirosint, UBRELVY, VOQUEZNA, VYVGART HYTRULO, Veozah, Vest Therapy Und, Wegovy | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error